



ACTG A5202

A Phase IIIB, Randomized, Trial of Open-Label Efavirenz or Atazanavir with Ritonavir in Combination with Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naïve Subjects

Brief Description: This study will be looking at first treatment combinations for HIV infection. Each patient will go into one of four groups. Each group will be taking a different set of HIV medications and you will know if you are taking Efavirenz or Atazanavir with Ritonavir., but you will not know if you are taking Abacavir/Lamivudine or Emtricitabine/Tenofovir. **Duration of Study:** Between 2 and 4 years (the study will end about 2 years after the last person starts the study)

Purpose of this Study: To learn whether the medication combinations work equally well in participants who have never taken HIV medications before. It will also look at how easy the medications are to take and their side effects.

Treatment:

Arm A: Efavirenz (Sustiva) 600 mg once daily + FTC (Emtricitabine) 200 mg/TDF (Tenofovir) 300 mg once daily + ABC (Abacavir)/3TC (Lamivudine) placebo once daily.

Arm B: Efavirenz (Sustiva) 600 mg + ABC (Abacavir) 600 mg/3TC (lamivudine) 300 mg once daily + FTC (Emtricitabine)/TDF (Tenofovir) placebo once daily.

Arm C: Atazanavir (Reyataz) 300 mg once daily with Ritonavir (Norvir) 100 mg once daily + FTC (Emtricitabine) 200 mg/TDF (Tenofovir) 300 mg once daily + ABC (Abacavir)/3TC (Lamivudine) placebo once daily.

Arm D: Atazanavir (Reyataz) 300 mg with Ritonavir (Norvir) 100 mg once daily +ABC (Abacavir) 600 mg/3TC (Lamivudine) 300 mg once daily + FTC (Emtricitabine)/TDF (Tenofovir) placebo once daily.

Requirements to Enter Study:

- Amount of HIV in blood is 1000 copies/mL or more.
- Never taken HIV medications (there are a few exceptions that you may discuss with the study staff).
- You will not be able to join, if you are already known to be resistant to any HIV medications.
- Pregnancy or breastfeeding is not allowed.
- Other requirements which your study coordinator will discuss with you.

Principal Investigator: Ardis Moe, MD

For More Information, call (310) 557-1891